Study of oseltamivir and zanamivir resistance-related mutations in influenza viruses isolated from wild mallards in Sweden

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Orozovic, Goran ^a   Orozovic, Kanita ^b   Järhult, Josef D ^a   Olsen, Björn ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ZANAMIVIR;

AMINO ACID SEQUENCE; ANAS PLATYRHYNCHOS; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; COLORIMETRY; CONTROLLED STUDY; GENOTYPE; IC 50; INFLUENZA VIRUS A; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; SWEDEN; VIRUS ISOLATION; VIRUS MUTATION; VIRUS STRAIN; WILD TYPE;

AMINO ACID SEQUENCE; ANALYSIS OF VARIANCE; ANIMALS; COLORIMETRY; DRUG RESISTANCE, VIRAL; DUCKS; GENOTYPE; INFLUENZA A VIRUS; INHIBITORY CONCENTRATION 50; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; NEURAMINIDASE; OSELTAMIVIR; SEQUENCE ALIGNMENT; SWEDEN; ZANAMIVIR;

EID: 84895881031     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089306     Document Type: Article

References (43)

1. Khanna M, Kumar B, Gupta N, Kumar P, Gupta A, et al. (2009) Pandemic swine influenza virus (H1N1): A threatening evolution. Indian Journal of Microbiology 49: 365-369.
2. Lewis DB (2006) Avian flu to human influenza. Annual Review of Medicine 57: 139-154.
3. Lee CW, Saif YA (2009) Avian influenza virus. Comparative Immunology Microbiology and Infectious Diseases 32: 301-310.
4. Olsen B, Munster VJ, Wallensten A, Waldenstrom J, Osterhaus A, et al. (2006) Global patterns of influenza A virus in wild birds. Science 312: 384-388.
5. Gubareva LV, Kaiser L, Hayden FG (2000) Influenza virus neuraminidase inhibitors. Lancet 355: 827-835. (Pubitemid 30128828)
6. Ward P, Small I, Smith J, Suter P, Dutkowski R (2005) Oseltamivir (Tamiflu (R)) and its potential for use in the event of an influenza pandemic. Journal of Antimicrobial Chemotherapy 55: 5-21.
7. von Itzstein M (2007) The war against influenza: discovery and development of sialidase inhibitors. Nature reviews Drug discovery 6: 967-974.
8. Moscona A (2008) Medical management of influenza infection. Annual Review of Medicine 59: 397-413.
9. Kramarz P, Monnet D, Nicoll A, Yilmaz C, Ciancio B (2009) Use of oseltamivir in 12 European countries between 2002 and 2007-lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses. Eurosurveillance 14.
10. Meijer A, Lackenby A, Hungnes O, Lina B, van der Werf S, et al. (2009) Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007-08 Season. Emerging Infectious Diseases 15: 552-560.
11. Dharan NJ, Gubareva LV, Meyer JJ, Okomo-Adhiambo M, McClinton RC, et al. (2009) Infections With Oseltamivir-Resistant Influenza A(H1N1) Virus in the United States. Jama-Journal of the American Medical Association 301: 1034-1041.
12. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, et al. (2008) Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrobial Agents and Chemotherapy 52: 3284-3292.
13. Weinstock DM, Zuccotti G (2009) The Evolution of Influenza Resistance and Treatment. Jama-Journal of the American Medical Association 301: 1066-1069.
14. Rameix-Welti MA, Enouf V, Cuvelier F, Jeannin P, van der Werf S (2008) Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. Plos Pathogens 4.
15. Moscona A (2009) Global Transmission of Oseltamivir-Resistant Influenza. New England Journal of Medicine 360: 953-956.
16. Fick J, Lindberg RH, Tysklind M, Haemig PD, Waldenstrom J, et al. (2007) Antiviral Oseltamivir Is not Removed or Degraded in Normal Sewage Water Treatment: Implications for Development of Resistance by Influenza A Virus. Plos One 2.
17. Sacca ML, Accinelli C, Fick J, Lindberg R, Olsen B (2009) Environmental fate of the antiviral drug Tamiflu in two aquatic ecosystems. Chemosphere 75: 28-33.
18. Ghosh GC, Nakada N, Yamashita N (2010) Oseltamivir Carboxylate, the Active Metabolite of Oseltamivir Phosphate (Tamiflu), Detected in Sewage Discharge and River Water in Japan. Environmental Health Perspectives 118: 103-108.
19. Soderstrom H, Jarhult JD, Olsen B, Lindberg RH, Tanaka H, et al. (2009) Detection of the Antiviral Drug Oseltamivir in Aquatic Environments. Plos One 4.
20. Singer AC, Nunn MA, Gould EA, Johnson AC (2007) Potential risks associated with the proposed widespread use of Tamiflu. Environmental Health Perspectives 115: 102-106. (Pubitemid 46050289)
21. Jarhult JD, Muradrasoli S, Wahlgren J, Soderstrom H, Orozovic G, et al. (2011) Environmental Levels of the Antiviral Oseltamivir Induce Development of Resistance Mutation H274Y in Influenza A/H1N1 Virus in Mallards. Plos One 6.
22. Gillman A, Muradrasoli S, Soderstrom H, Nordh J, Brojer C, et al. (2013) Resistance Mutation R292K Is Induced in Influenza A(H6N2) Virus by Exposure of Infected Mallards to Low Levels of Oseltamivir. Plos One 8.
23. Järhult JD (2012) Oseltamivir (Tamiflu H) in the environment, resistance development in influenza A viruses of dabbling ducks and the risk of transmission of an oseltamivir-resistant virus to humans-a review. Infection Ecology and Epidemiology 2.
24. Taubenberger JK, Morens DM (2009) Pandemic influenza - including a risk assessment of H5N1. Revue Scientifique Et Technique-Office International Des Epizooties 28: 187-202.
25. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, et al. (2009) Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans. Science 325: 197-201.
26. Orozovic G, Orozovic K, Lennerstrand J, Olsen B (2011) Detection of resistance mutations to antivirals oseltamivir and zanamivir in the avian influenza A viruses isolated from wild birds. Plos One 6.
27. Wallensten A, Munster VJ, Latorre-Margalef N, Brytting M, Elmberg J, et al. (2007) Surveillance of influenza A virus in migratory waterfowl in northern Europe. Emerging Infectious Diseases 13: 404-411. (Pubitemid 46348127)
28. Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR (2001) Universal primer set for the full-length amplification of all influenza A viruses. Archives of Virology 146: 2275-2289. (Pubitemid 34682391)
29. Orozovic G, Latorre-Margalef N, Wahlgren J, Muradrasoli S, Olsen B (2010) Degenerate primers for PCR amplification and sequencing of the avian influenza A neuraminidase gene. Journal of Virological Methods 170: 95-99.
30. Ferraris O, Lina B (2008) Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. Journal of Clinical Virology 41: 13-19. (Pubitemid 350298978)
31. Hurt AC, Holien JK, Barr IG (2009) In Vitro Generation of Neuraminidase Inhibitor Resistance in A(H5N1) Influenza Viruses. Antimicrobial Agents and Chemotherapy 53: 4433-4440.
32. Ilyushina NA, Seiler JP, Rehg JE, Webster RG, Govorkova EA (2010) Effect of Neuraminidase Inhibitor-Resistant Mutations on Pathogenicity of Clade 2.2 A/Turkey/15/06 (H5N1) Influenza Virus in Ferrets. Plos Pathogens 6.
33. Richard M, Deleage C, Barthelemy M, Lin YP, Hay A, et al. (2008) Impact of influenza A virus neuraminidase mutations on the stability, activity, and sensibility of the neuraminidase to neuraminidase inhibitors. Journal of Clinical Virology 41: 20-24. (Pubitemid 50009219)
34. Yen HL, Hoffmann E, Taylor G, Scholtissek C, Monto AS, et al. (2006) Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. Journal of Virology 80: 8787-8795. (Pubitemid 44384887)
35. Warren L (1959) Thiobarbituric Acid Assay of Sialic Acids. Journal of Biological Chemistry 234: 1971-1975.
36. Webster R, Cox N, Störh K (2002) WHO Manual on Animal Influenza Diagnosis and Surveillance.WHO/CDS/CSR/NCS/2002.5 Rev. 1. 40-47.
37. Nguyen HT, Sheu TG, Mishin VP, Klimov AI, Gubareva LV (2010) Assessment of Pandemic and Seasonal Influenza A (H1N1) Virus Susceptibility to Neuraminidase Inhibitors in Three Enzyme Activity Inhibition Assays. Antimicrobial Agents and Chemotherapy 54: 3671-3677.
38. Mishin VP, Hayden FG, Gubareva LV (2005) Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrobial Agents and Chemotherapy 49: 4515-4520. (Pubitemid 41552580)
39. Ferraris O, Kessler N, Lina B (2005) Sensitivity of influenza viruses to zanamivir and oseltamivir: A study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antiviral Research 68: 43-48. (Pubitemid 41338581)
40. Stoner T, D., Krauss S, DuBois Rebecca M, Negovetich Nicholas J, Stallknecht David E, et al. (2010) Antiviral Susceptibility of Avian and Swine Influenza Virus of the N1 Neuraminidase Subtype. Journal of Virology 84: 9800-9809.
41. Govorkova EA, Leneva IA, Goloubeva OG, Bush K, Webster RG (2001) Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrobial Agents and Chemotherapy 45: 2723-2732. (Pubitemid 32906663)
42. Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, et al. (2006) The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443: 45-49. (Pubitemid 44344043)
43. Wagner R, Matrosovich M, Klenk HD (2002) Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Reviews in Medical Virology 12: 159-166. (Pubitemid 34516947)